IN8BIO, INC.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock(1) · AdditionalPaid-In · Accumulated · Total | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Stockholders' Equity | |
| Balance at December 31, 2023 | 1,442,929 | $4 | $116,152 | $(91,219) | $24,937 |
| Issuance costs | — | — | (89) | — | (89) |
| Stock-based compensation expense | — | — | 1,240 | — | 1,240 |
| Net loss | — | — | — | (8,562) | (8,562) |
| Balance at March 31, 2024 | 1,442,929 | 4 | 117,303 | (99,781) | 17,526 |
| Issuance of common stock, net of issuance costs | 104,234 | 1 | 3,527 | — | 3,528 |
| Issuance of common stock upon exercise of Series A warrants, net of issuance costs | 666 | — | 25 | — | 25 |
| Stock-based compensation expense | — | — | 1,171 | — | 1,171 |
| Net loss | — | — | — | (8,629) | (8,629) |
| Balance at June 30, 2024 | 1,547,829 | 5 | 122,026 | (108,410) | 13,621 |
| Issuance of common stock, net of issuance costs | 11,743 | — | 289 | — | 289 |
| Stock-based compensation expense | — | — | 1,764 | — | 1,764 |
| Net loss | — | — | — | (7,086) | (7,086) |
| Balance at September 30, 2024 | 1,559,572 | $5 | $124,079 | $(115,496) | $8,588 |
| Balance at December 31, 2024 | 2,416,066 | $7 | $136,127 | $(121,656) | $14,478 |
| Issuance of common stock, net of issuance costs | 245,428 | 1 | 3,734 | — | 3,735 |
| Issuance of common stock upon exercise of Series C warrants, net of issuance costs | 47,088 | — | 383 | — | 383 |
| Stock-based compensation expense | — | — | 831 | — | 831 |
| Net loss | — | — | — | (5,550) | (5,550) |
| Balance at March 31, 2025 | 2,708,582 | 8 | 141,075 | (127,206) | 13,877 |
| Issuance of common stock, net of issuance costs | 1,058,861 | 2 | 3,615 | — | 3,617 |
| Issuance of common stock upon exercise of Series A & B warrants, net of issuance costs | 310,696 | — | 1,884 | — | 1,884 |
| Stock-based compensation expense | — | — | 955 | — | 955 |
| Net loss | — | — | — | (5,094) | (5,094) |
| Balance at June 30, 2025 | 4,078,139 | 10 | 147,529 | (132,300) | 15,239 |
| Issuance of common stock, net of issuance costs | 511,057 | — | 1,112 | — | 1,112 |
| Stock-based compensation expense | — | — | 692 | — | 692 |
| Net loss | — | — | — | (3,854) | (3,854) |
| Balance at September 30, 2025 | 4,589,196 | $10 | $149,333 | $(136,154) | $13,189 |
(1) All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect a one-for-thirty reverse stock split effected in June 2025. See Note 1, Organization and Nature of Operations, for details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.